Clinically approved bone-modifying agents for the treatment of MBD include bisphosphonates56, which inhibit bone resorption by suppressing OC activity, and denosumab57, a monoclonal antibody against the osteoclastogenic cytokine RANKL. Here, TNFSF11 is linked to Marchiafava-Bignami disease.